PANTŮČEK, Roman, Milada DVOŘÁČKOVÁ, Martin BENEŠÍK, Jiří DOŠKAŘ, Ivana MAŠLAŇOVÁ, Vladislava RŮŽIČKOVÁ, Filip RŮŽIČKA and Marek MOŠA. Characterization of in vitro lytic activity of bacteriophage preparation STAFAL against Staphylococcus aureus. In Molecular Genetics of Bacteria and Phages. 2013.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Characterization of in vitro lytic activity of bacteriophage preparation STAFAL against Staphylococcus aureus
Authors PANTŮČEK, Roman, Milada DVOŘÁČKOVÁ, Martin BENEŠÍK, Jiří DOŠKAŘ, Ivana MAŠLAŇOVÁ, Vladislava RŮŽIČKOVÁ, Filip RŮŽIČKA and Marek MOŠA.
Edition Molecular Genetics of Bacteria and Phages, 2013.
Other information
Original language English
Type of outcome Conference abstract
Field of Study Genetics and molecular biology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Organization unit Faculty of Science
Changed by Changed by: prof. RNDr. Roman Pantůček, Ph.D., učo 842. Changed: 11/10/2013 15:44.
Abstract
Staphylococcus aureus is one of the most common gram-positive opportunistic pathogens in humans causing from minor skin to severe systemic infections. The newly acquired genes responsible for virulence and resistance to antibiotics are rapidly disseminated in the staphylococcal population and multiple-resistant S. aureus strains represent a significant medical problem. Bacteriophages with a broad host range are suitable for fighting these pathogenic bacteria as an alternative to antibiotic therapy. In this work we summarize the results of susceptibility testing of S. aureus strains to bacteriophage preparation STAFAL in a routine clinical microbiology laboratory. STAFAL is an antistaphylococcal phage lysate for topical application produced under GMP by IMUNA s.r.o. in the Czech Republic, containing highly effective virulent phage particles with a strong and rapid lytic and polyvalent effect. A set of 400 S. aureus strains collected from 10 health-care facilities in Brno (Czech Republic) during 2011 -2013 , including isolates from outpatients' and inpatients' departments was tested in this work.
Links
NT12395, research and development projectName: Molekulární průkaz a analýza invazivních kmenů small colony variants (SCV) a rezistentních kmenů S. aureus od pacientů s cystickou fibrózou
TA01010405, research and development projectName: Výzkum stafylokokových bakteriofágových mutant s širokým spektrem hostitelů (Acronym: TAČR/IMUNA-1)
Investor: Technology Agency of the Czech Republic
PrintDisplayed: 14/7/2024 05:09